Autoimmune bullous diseases in non‐HIVKaposi's sarcoma: a retrospective study in a large cohort of patients

Abstract

Bullous diseases seem to be more frequent among patients with KS, supporting the hypothesis that HHV-8 may be involved in their pathogenesis. Therapeutic management of these cases should take into account KS-inducing potential of corticosteroids.

Muriel Sidnoma Ouédraogo, Nakougou Moϊ-Bohm Biatougou, Nomtondo Amina Ouédraogo, Angèle Ouangré/Ouédraogo, Gilbert Patrice Marie Louis Tapsoba, Adama Traoré, Fatimata Cissé, Nina Korsaga/Somé, Pascal Niamba, Jacques Simporé, Adama Traoré

“…The iatrogenic subtype of KS was originally described in patients who had undergone organ transplantation, in particular kidney transplants followed by high-dose immunosuppressants [9]. Since then, several other cases have been reported in patients who have not had organ transplantation yet have been receiving immunosuppressants, including systemic and topical corticosteroids, for a variety of disorders (blood diseases, kidney diseases, atopic dermatitis, asthma, chronic inflammatory disease [8,[10][11][12][13][14].…”

Extensive cutaneous iatrogenic Kaposi’s sarcoma after bullous pemphigoid treatment with oral methylprednisolone: a rare Chinese case report

“…24 Half of these 14 patients developed KS after the onset of bullous disease, whereas the other half developed a bullous disease after being diagnosed with KS. 24 Only a few cases on concurrent HHV-8 and BP have been reported in the literature. 12,21,22 HHV-8 identification in KS with BP has been reported only in one patient in the Chinese population.…”

“…23 A recent retrospective study in non-HIV KS patients reported that 14 (1.03%) of 1362 patients with classic or iatrogenic KS also suffered from bullous disease. 24 Half of these 14 patients developed KS after the onset of bullous disease, whereas the other half developed a bullous disease after being diagnosed with KS. 24 Only a few cases on concurrent HHV-8 and BP have been reported in the literature.…”

Successful treatment of HIV-negative Kaposi sarcoma with ipilimumab and nivolumab and concurrent management of baseline psoriasis and bullous pemphigoid

“…This is particularly pertinent given the increased incidence of autoimmune bullous diseases in patients with noneHIV-associated KS. 6 As immunotherapies are being increasingly developed, we must find ways to leverage therapeutic benefits in rare diseases such as KS. Further trials are warranted to explore checkpoint inhibition in KS, especially whether cytotoxic T-lymphocyteeassociated protein 4 inhibition enhances programmed cell death protein 1 inhibition to lead to further cytotoxic T-cell destruction of KS-infected cells.…”